FDA Approves Galliprant, a New Animal Drug for Osteoarthritis in Dogs
March 21, 2016
The U.S. Food and Drug Administration today announced the approval of Galliprant (grapiprant tablets), a new animal drug intended to control pain and inflammation associated with osteoarthritis in dogs.
Osteoarthritis (OA) is a condition where cartilage – the protective material that cushions a joint – breaks down over time, causing the bones to rub against each other. This rubbing can permanently damage the joint and cause pain, inflammation, and lameness. Older and overweight dogs are at a higher risk of developing OA.
A new treatment option for dogs with OA, Galliprant is a prostaglandin E2 (PGE2) EP4 receptor antagonist; a non-cyclooxygenase inhibiting, non steroidal anti-inflammatory drug (NSAID). All NSAIDs carry certain risks, including vomiting, diarrhea, not eating/eating less, and lethargy. These drugs must be prescribed by a licensed veterinarian, because professional expertise is needed to diagnose and provide guidance in the control of OA pain.
Other NSAIDs that are FDA-approved for use in dogs include deracoxib (Deramaxx), carprofen (Rimadyl, Novocox, Carprieve, Quellin, Carprofen), meloxicam (Metacam, Loxicom, Orocam, Meloxidyl, Meloxicam), and firocoxib (Previcox).
The application for Galliprant is sponsored by Aratana Therapeutics.